164 related articles for article (PubMed ID: 31002954)
1.
Manoharan P; Salem A; Mistry H; Gornall M; Harden S; Julyan P; Locke I; McAleese J; McMenemin R; Mohammed N; Snee M; Woods S; Westwood T; Faivre-Finn C
J Thorac Oncol; 2019 Jul; 14(7):1296-1305. PubMed ID: 31002954
[TBL] [Abstract][Full Text] [Related]
2. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
3. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of neutrophil/lymphocyte ratio (NLR) and correlation with PET-CT metabolic parameters in small cell lung cancer (SCLC).
Mirili C; Guney IB; Paydas S; Seydaoglu G; Kapukaya TK; Ogul A; Gokcay S; Buyuksimsek M; Yetisir AE; Karaalioglu B; Tohumcuoglu M
Int J Clin Oncol; 2019 Feb; 24(2):168-178. PubMed ID: 30109543
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
6. Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI.
Ohno Y; Yoshikawa T; Takenaka D; Koyama H; Aoyagi K; Yui M; Oshima Y; Hamabuchi N; Tanaka Y; Shigemura C; Oota S; Nomura M; Murayama K; Inui Y; Kikukawa K; Toyama H
AJR Am J Roentgenol; 2022 May; 218(5):899-908. PubMed ID: 34877872
[No Abstract] [Full Text] [Related]
7. Performance Comparison Between
Kishida Y; Seki S; Yoshikawa T; Itoh T; Maniwa Y; Nishimura Y; Ohno Y
AJR Am J Roentgenol; 2018 Jul; 211(1):185-192. PubMed ID: 29667886
[TBL] [Abstract][Full Text] [Related]
8. Dual-Energy Computed Tomography-Based Iodine Quantitation for Response Evaluation of Lung Cancers to Chemoradiotherapy/Radiotherapy: A Comparison With Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-Based Positron Emission Tomography/Computed Tomography Response Evaluation Criterion in Solid Tumors.
Ren Y; Jiao Y; Ge W; Zhang L; Hua Y; Li C; Zhai W; Tang X; He W; Fang M; Zheng X
J Comput Assist Tomogr; 2018; 42(4):614-622. PubMed ID: 29613988
[TBL] [Abstract][Full Text] [Related]
9. Impact of PET staging in limited-stage small-cell lung cancer.
Xanthopoulos EP; Corradetti MN; Mitra N; Fernandes AT; Kim M; Grover S; Christodouleas JP; Evans TL; Stevenson JP; Langer CJ; Lee TT; Pryma DA; Lin LL; Simone CB; Apisarnthanarax S; Rengan R
J Thorac Oncol; 2013 Jul; 8(7):899-905. PubMed ID: 23608814
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
11. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of standardised uptake value (SUV
Yilmaz Demirci N; Yilmaz Ü; Biner Uslu I; Dikmen A; Yılmaz A; Erdoğan Y
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26988938
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of FIGO staging defined by combining MRI and [
Raffa S; Lanfranchi F; Satragno C; Giannelli F; Marcenaro M; Coco A; Cena SE; Sofia L; Marini C; Mammoliti S; Levaggi A; Tagliafico AS; Sambuceti G; Barra S; Morbelli S; Belgioia L; Bauckneht M
Curr Probl Cancer; 2023 Dec; 47(6):101007. PubMed ID: 37684197
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of metabolic parameters measured by
Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study.
Quartuccio N; Evangelista L; Alongi P; Caobelli F; Altini C; Cistaro A; Lambertini A; Schiorlin I; Popescu CE; Linguanti F; Laudicella R; Scalorbi F; Di Pierro G; Asabella AN; Cuppari L; Margotti S; Lima GM; Scalisi S; Pacella S; Kokomani A; Ciaccio A; Sturiale L; Vento A; Cardile D; Baldari S; Panareo S; Fanti S; Rubini G; Schillaci O; Chiaravalloti A;
Nucl Med Commun; 2019 Aug; 40(8):808-814. PubMed ID: 31136534
[TBL] [Abstract][Full Text] [Related]
16. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
17. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
Oh JR; Seo JH; Chong A; Min JJ; Song HC; Kim YC; Bom HS
Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):925-35. PubMed ID: 22270509
[TBL] [Abstract][Full Text] [Related]
18. Extra-thoracic tumor burden but not thoracic tumor burden on (18)F-FDG PET/CT is an independent prognostic biomarker for extensive-disease small cell lung cancer.
Oh JR; Seo JH; Hong CM; Jeong SY; Lee SW; Lee J; Min JJ; Song HC; Bom HS; Kim YC; Ahn BC
Lung Cancer; 2013 Aug; 81(2):218-25. PubMed ID: 23731740
[TBL] [Abstract][Full Text] [Related]
19. Effect of Midtreatment PET/CT-Adapted Radiation Therapy With Concurrent Chemotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial.
Kong FM; Ten Haken RK; Schipper M; Frey KA; Hayman J; Gross M; Ramnath N; Hassan KA; Matuszak M; Ritter T; Bi N; Wang W; Orringer M; Cease KB; Lawrence TS; Kalemkerian GP
JAMA Oncol; 2017 Oct; 3(10):1358-1365. PubMed ID: 28570742
[TBL] [Abstract][Full Text] [Related]
20. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
